1. Home
  2. KSS vs MLYS Comparison

KSS vs MLYS Comparison

Compare KSS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kohl's Corporation

KSS

Kohl's Corporation

HOLD

Current Price

$16.63

Market Cap

2.0B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.47

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSS
MLYS
Founded
1962
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
KSS
MLYS
Price
$16.63
$27.47
Analyst Decision
Sell
Strong Buy
Analyst Count
15
7
Target Price
$15.31
$48.67
AVG Volume (30 Days)
3.9M
1.6M
Earning Date
05-28-2026
05-06-2026
Dividend Yield
3.58%
N/A
EPS Growth
142.86
37.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.19
$12.59
52 Week High
$25.22
$47.65

Technical Indicators

Market Signals
Indicator
KSS
MLYS
Relative Strength Index (RSI) 48.83 50.72
Support Level $14.22 $25.88
Resistance Level $16.64 $31.29
Average True Range (ATR) 0.95 1.50
MACD -0.33 0.27
Stochastic Oscillator 22.38 44.21

Price Performance

Historical Comparison
KSS
MLYS

About KSS Kohl's Corporation

Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: